enGene expands loan facility to $125M; draws $25M initial tranche with Hercules Capital

enGene Therapeutics Inc.

Second Amendment increases term loan facility from $50M to up to $125M, with initial $25M advance to refinance prior debt.
New loans mature January 1, 2030; interest rate is prime + 2.25% (min 9.25%, capped at 10.25%).
End-of-term fee of 5.95% of aggregate principal; additional tranches tied to clinical, approval, and commercial milestones.
Issued 40,850 warrants at $9.18/share to Lenders as part of initial draw; up to 204,248 warrants possible if fully drawn.
Loan secured by substantially all assets including intellectual property; Hercules Capital acts as agent.

item 1.01item 2.03item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.